PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Arcinova Appoints Christian Dowdeswell as New Managing Director

Arcinova, a Quotient Sciences company, and UK-based Contract Research Development and Manufacturing Organisation (CRDMO), has announced the appointment of Dr. Christian Dowdeswell as new Managing Director.

Taking the reins from co-founder and Managing Director, Paul Ryan, who recently announced his retirement, Christian joins the firm at a busy time for the business which has recently relaunched with a refreshed brand identity and a renewed focus on delivering integrated drug substance and early drug product services to global biotech and pharmaceutical partners

.

Over the past 3–4 years, under Quotient Sciences, the Arcinova facility in Alnwick has received £6.3 million of investment to establish a world-class, 1,500 square-meter GMP manufacturing suite. This state-of-the-art facility now houses 14 GMP manufacturing streams, enabling the production of drug substance from small-scale PR&D batches to multi-kilo quantities, supporting clients from early development through to Proof of Concept.

More recently, they have enhanced their aseptic capabilities to ensure full compliance with the latest Annex 1 requirements, further strengthening their ability to support complex and high-quality manufacturing needs.

Commenting on his appointment, Christian said: “Arcinova has an outstanding reputation for innovation, agility, and scientific excellence—qualities our clients depend on. Paul has built a strong foundation for success, and I’m committed to building on that momentum, driving growth while keeping our customers at the heart of everything we do.”

Bringing over 25 years of sector experience to his role, Christian joins Arcinova from consulting and advisory positions with companies including Nanoform and Pangaea Life Sciences. Prior to this, he was Chief Business Officer Drug Substances at global life sciences company Siegfried AG, and held various senior positions with Lonza, most recently as Vice President and Global Head of Commercial Development of Lonza’s small molecules custom manufacturing business.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, commented: “Christian is a welcome addition to the team and joins Arcinova at an exciting time for the business. He brings a wealth of experience and knowledge of the global CDMO market to the role.

“Christian’s leadership will be instrumental as Arcinova continues to grow and deliver client service excellence, as we help our customers accelerate the development of new medicines” continued Van Nieuwenhove.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026